SCHEMBL13041385

SCHEMBL13041385

Cc1c(-c2nc3ccccc3[nH]2)c(=O)[nH]c2ccc(Cl)cc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 9/20 0.60
PDGFRB P09619 8/20 0.56
FGFR1 P11362 8/20 0.56
KDR P35968 8/20 0.56
FLT1 P17948 2/20 0.56
KDM4E B2RXH2 1/20 0.51
MEN1 O00255 1/20 0.51
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
MAPT P10636 1/20 0.51
HPGD P15428 1/20 0.51
KMT2A Q03164 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
HSD17B10 Q99714 1/20 0.51
CSF1R P07333 2/20 0.49
PTGS2 P35354 1/20 0.48
IKBKB O14920 1/20 0.48
CHUK O15111 1/20 0.48
AKT1 P31749 1/20 0.48
AKT2 P31751 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13041330 0.88 FGFR1 (0.63) CHEK1PDGFRBFGFR1KDRFLT1
SCHEMBL12879833 0.86 FGFR1 (0.70) CHEK1PDGFRBFGFR1KDRFLT1
SCHEMBL1055018 0.85 FGFR1 (0.74) CHEK1PDGFRBFGFR1KDRFLT1
SCHEMBL14268438 0.84 CHEK1 (0.59) CHEK1PDGFRBFGFR1KDRFLT1
SCHEMBL13041337 0.84 FGFR1 (0.55) CHEK1PDGFRBFGFR1KDRFLT1
SCHEMBL13041342 0.84 FGFR1 (0.59) CHEK1PDGFRBFGFR1KDRFLT1
SCHEMBL13041331 0.82 FGFR1 (0.53) CHEK1PDGFRBFGFR1KDRFLT1
SCHEMBL13041329 0.82 FGFR1 (0.56) CHEK1PDGFRBFGFR1KDRFLT1
SCHEMBL1050109 0.81 CHEK1 (0.66) CHEK1PDGFRBFGFR1KDRFLT1
SCHEMBL14795537 0.78 CHEK1 (0.63) CHEK1PDGFRBFGFR1KDRFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825132-B2 Inhibition of FGFR3 and treatment of multiple myeloma NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-11-02 US disclosed
US-20090281100-A1 Benzimidazole quinolinones and uses thereof BARSANTI PAUL A 2009-11-12 US disclosed
US-7470709-B2 Benzimidazole quinolinones and uses thereof NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281100-A1 Benzimidazole quinolinones and uses thereof GAA, ALPI, IL4I1 CHEK1 2358/4885PDGFRB 3508/4885FGFR1 3018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.